We’re proud to share Patrick A. Baeuerle, PhD, our Co-Founder and Chief Scientific Advisor, was recognized again this year by Research.com’s 2024 Ranking of Best Scientists in the field of #Biology and #Biochemistry. With more than 30 years in the industry, Patrick has been published in hundreds of peer-reviewed scientific papers that have been cited more than 83,000 times. This impressive body of evidence underscores his commitment to transformative scientific progress. Learn more about Patrick’s accomplishments and contributions to the industry here: https://bit.ly/3zG6azL
Cullinan Therapeutics
Biotechnology Research
Cambridge, Massachusetts 6,730 followers
Modality-Agnostic Targeted Therapeutics
About us
Cullinan Therapeutics is dedicated to creating new standards of care for patients. We have strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Our portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of cancer and autoimmune indications. Notice to Job Seekers: Job applicants should be aware of job recruitment, interview and offer scams being perpetrated through the use of the internet and social media platforms. To learn more, visit our Careers page or read Cullinan’s Employment Recruitment Scams Notice here: https://cullinantherapeutics.com/docs/employment-recruitment-scams-notice.pdf
- Website
-
http://www.cullinantherapeutics.com
External link for Cullinan Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Specialties
- Oncology and Auto-Immune Diseases
Locations
-
Primary
1 Main St
Cambridge, Massachusetts 02142, US
Employees at Cullinan Therapeutics
Updates
-
In case you missed Sachs Associates’ Annual Oncology Innovation Forum, be sure to watch the full panel discussion, “New Endpoints for Early-Stage Oncology Companies” featuring Nadim Ahmed, President and CEO. #Sachs_OIF
We are delighted to share the New Endpoints for Early-Stage Oncology Companies Panel from the 10th Annual Oncology Innovation Forum. Chaired by: Jeff Bockman, EVP Expert Advisor, Oncology, Lumanity Head, Oncology Center of Excellence, Lumanity Panellists: Colette Lipp, Director, Global BD Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany Jim Barlow, President & CEO, ImmunoGenesis, Inc. Matthew Price, Co-Founder, EVP & Chief Operating Officer, Promontory Therapeutics Inc. Nadim Ahmed, President & CEO, Cullinan Therapeutics, Inc. Raven Lin, Co-Founder & CEO, Pilatus Biosciences SA View here: https://lnkd.in/d8q8SAcz #OncologyEndpoints #EarlyStageOncology #CancerResearch #BiotechInnovation #Pharma #SachsForum #ASCO2024
New Endpoints for Early-Stage Oncology Companies Panel @ Sachs_OIF
https://www.youtube.com/
-
This Pride Month, we want to thank our guest speakers from SpeakOUT Boston who joined us to share their personal stories and shed light on the challenges faced by LGBTQ+ individuals in the workplace. At Cullinan, we’re committed to cultivating an environment where everyone can feel seen, heard, and valued. As part of this commitment, we provide learning opportunities and support systems to enhance cultural competence and allyship within our organization and community. SpeakOUT reminded us that being an ally is not a noun, it’s a verb – our actions speak louder than words. We hope you will join us this Pride Month and beyond in taking action to ensure everyone in your community feels safe, supported, and celebrated for who they are. Happy Pride Month!
-
-
Team Cullinan was proud to participate in the 2024 Kendall Square Challenge earlier this month. Our team helped raise funds to support local nonprofit InnerCity Weightlifting (ICW). Thank you Kendall Square Association for hosting such a fun way to give back to our community!
-
-
Today, on Juneteenth, as part of our ongoing efforts to support organizations in our local community, we are proud to share that we have once again made a contribution to We Got Us. This Boston-based student-led coalition is dedicated to increasing access to equitable healthcare, community-centered health education, and direct healing for Black communities. We are committed to working towards a future where everyone has access to high-quality care, regardless of their race or socioeconomic status. We know that this work requires sustained effort and a willingness to listen, learn, and take action.
-
-
One of our core company values is innovation without borders to develop novel therapies. On June 17, Jennifer Michaelson, our Chief Scientific Officer, will participate in a panel discussion on innovation in drug discovery as part of Longwood Healthcare Leaders’ #SpringMIT event. Click to learn more about Spring MIT.
Join CSO Jen Michaelson for a Longwood Healthcare Leaders Panel Discussion
longwoodhealthcareleaders.com
-
CEO Nadim Ahmed caught up with Brad Loncar of BiotechTV at #ASCO24 to discuss data Cullinan presented at this year’s conference & strategic expansion into autoimmune diseases. Check out the interview and learn more about Cullinan’s strategy and pipeline: https://bit.ly/455o5LY
𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟒: The Cullinan Therapeutics CEO Nadim Ahmed discusses two data sets at #ASCO24 and the rationale for a T-cell engager for autoimmune disease. He describes #ASCO24 data from today for CLN-619 and zipalertinib, and discusses taking a CD19/CD3 into the clinic for lupus. Full video: https://lnkd.in/gUM8eTKM BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
Join us today at 6:30 p.m. CT for our investor event at #ASCO24 where we will take a deep dive into new clinical data for CLN-619 and zipalertinib. A live webcast and recording will be available here: https://bit.ly/4bD5WHU
Cullinan Therapeutics Hosting Investor Briefing Today at ASCO 2024
https://cullinantherapeutics.com
-
Today at #ASCO24, we will present the first clinical data for CLN-619, a novel anti-MICA/B antibody, in combination with a checkpoint inhibitor and updated monotherapy data from our Phase 1 study in patients with advanced solid tumors. Join our poster presentation between 9 a.m. and 12 p.m. CT today. Learn more here: https://bit.ly/454ITmW
Cullinan Therapeutics to Present Data Today at ASCO 2024
cullinantherapeutics.com
-
Today, we announced positive initial data in patients receiving zipalertinib after prior treatment with amivantamab enrolled in our pivotal Phase 2b REZILIENT1 clinical trial. Learn more here.
Positive Initial Data from Phase 2b REZILIENT1 Study of Zipalertinib
investors.cullinantherapeutics.com